EpCAM is a well-characterized surface marker of liver cancer cells, and the presence of EpCAM-positive CTCs has been previously associated with vascular invasion, increased serum AFP [21,34,35], more advanced HCC stage, and increased recurrence rates after surgery [21,36]. Here, AFP is linked to liver cancer.